[go: up one dir, main page]

AU2003231252A1 - Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease - Google Patents

Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease

Info

Publication number
AU2003231252A1
AU2003231252A1 AU2003231252A AU2003231252A AU2003231252A1 AU 2003231252 A1 AU2003231252 A1 AU 2003231252A1 AU 2003231252 A AU2003231252 A AU 2003231252A AU 2003231252 A AU2003231252 A AU 2003231252A AU 2003231252 A1 AU2003231252 A1 AU 2003231252A1
Authority
AU
Australia
Prior art keywords
alzheimer
disease
prevention
compositions
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003231252A
Inventor
Eyal S. Ron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
eNOS Pharmaceuticals Inc
Original Assignee
eNOS Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by eNOS Pharmaceuticals Inc filed Critical eNOS Pharmaceuticals Inc
Publication of AU2003231252A1 publication Critical patent/AU2003231252A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003231252A 2002-05-09 2003-05-02 Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease Abandoned AU2003231252A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37968402P 2002-05-09 2002-05-09
US60/379,684 2002-05-09
PCT/US2003/013689 WO2003094909A2 (en) 2002-05-09 2003-05-02 Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease

Publications (1)

Publication Number Publication Date
AU2003231252A1 true AU2003231252A1 (en) 2003-11-11

Family

ID=29420551

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003231252A Abandoned AU2003231252A1 (en) 2002-05-09 2003-05-02 Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease

Country Status (2)

Country Link
AU (1) AU2003231252A1 (en)
WO (1) WO2003094909A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
PE20110235A1 (en) 2006-05-04 2011-04-14 Boehringer Ingelheim Int PHARMACEUTICAL COMBINATIONS INCLUDING LINAGLIPTIN AND METMORPHINE
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN109503584A (en) 2006-05-04 2019-03-22 勃林格殷格翰国际有限公司 Polymorphic
AR071175A1 (en) 2008-04-03 2010-06-02 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION THAT INCLUDES AN INHIBITOR OF DIPEPTIDIL-PEPTIDASA-4 (DPP4) AND A COMPARING PHARMACO
KR20200118243A (en) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 Treatment for diabetes in patients inappropriate for metformin therapy
UY32030A (en) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
TWI508965B (en) 2008-12-23 2015-11-21 Boehringer Ingelheim Int Salt form of organic compound
AR074990A1 (en) 2009-01-07 2011-03-02 Boehringer Ingelheim Int TREATMENT OF DIABETES IN PATIENTS WITH AN INAPPROPRIATE GLUCEMIC CONTROL THROUGH METFORMIN THERAPY
EP2504002B1 (en) 2009-11-27 2019-10-09 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
AU2011249722B2 (en) 2010-05-05 2015-09-17 Boehringer Ingelheim International Gmbh Combination therapy
ES2802243T3 (en) 2010-06-24 2021-01-18 Boehringer Ingelheim Int Diabetes therapy
AR083878A1 (en) 2010-11-15 2013-03-27 Boehringer Ingelheim Int VASOPROTECTORA AND CARDIOPROTECTORA ANTIDIABETIC THERAPY, LINAGLIPTINA, TREATMENT METHOD
KR101985384B1 (en) 2011-07-15 2019-06-03 베링거 인겔하임 인터내셔날 게엠베하 Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP2908806A1 (en) * 2012-10-09 2015-08-26 Boehringer Ingelheim International GmbH Use of selectively moisture-adjusted tabletting material in the production of mechanically stable tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing tablets
ES2950384T3 (en) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Medical use of a DPP-4 inhibitor
CN109310697A (en) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 Combination of linagliptin and metformin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2401697A (en) * 1996-06-20 1998-01-07 Pfizer Inc. 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors

Also Published As

Publication number Publication date
WO2003094909A2 (en) 2003-11-20
WO2003094909A3 (en) 2004-04-01

Similar Documents

Publication Publication Date Title
AU2003231252A1 (en) Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
EP1392287B8 (en) Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease
WO2003072035A8 (en) Compositions and methods for the treatment of immune related diseases
WO2004041170A9 (en) Compositions and methods for the treatment of immune related diseases
AU2003220096A1 (en) Methods for alzheimer's disease treatment and cognitive enhancement
WO2004024097A9 (en) Compositions and methods for the treatment of immune related diseases
AU2003206413A1 (en) Substituted amino carboxamides for the treatment of alzheimer's disease
AU2002243023A1 (en) Compositions for preventing and/or treating oral diseases
IL158181A0 (en) N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
AU2002315131A1 (en) Aminediols as agents for the treatment of alzheimer's disease
PL371281A1 (en) Methods and compositions for the treatment of eye diseases
AU2003303141A1 (en) Hydroxypropyl amides for the treatment of alzheimer's disease
AU2003273310A1 (en) Substituted aminoethers for the treatment of alzheimer's disease
AU2003248660A1 (en) Treatment of vascular dysfunction and alzheimer's disease
AU4228000A (en) Methods and compositions for the treatment and prevention of lung disease
PL377110A1 (en) Prevention and treatment of alzheimer's disease
AU2003248893A8 (en) Compositions and methods for the treatment of parkinson's disease and tardive dyskinesias
AU2003299101A1 (en) Compounds for the treatment of alzheimer's disease
AU4225500A (en) Methods and compositions for the treatment and prevention of lung disease
AU2003230848A1 (en) Methods and compositions for treating alzheimer's disease
AU2003289889A1 (en) Methods for the treatment of alzheimers disease and compositions therefore
AU2003286530A1 (en) Substituted peptides useful in the treatment of alzheimer's disease
AU2002348324A1 (en) Methods and compositions for the treatment and diagnosis of pain disorders using 46566
AU2003223330A1 (en) Compositions and method of treating alzheimer's disease

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 18, NO 2, PAGE(S) 509 UNDER THE HEADING APPLICATIONS OPI - NAME INDEX UNDER THE NAME ENOS PHARMACEUTICALS, INC., APPLICATION NO. 2003231252, UNDER INID(43) CORRECT THE PUBLICATION DATE TO READ 24.11.2003